MADRIGAL PHARMACEUTICALS INC's ticker is MDGL and the CUSIP is 558868105. A total of 126 filers reported holding MADRIGAL PHARMACEUTICALS INC in Q2 2020. The put-call ratio across all filers is 0.56 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $4,342 | -52.5% | 15,496 | -54.7% | 0.00% | -66.7% |
Q1 2024 | $9,139 | +3.0% | 34,223 | -10.8% | 0.00% | 0.0% |
Q4 2023 | $8,874 | +130.0% | 38,354 | +45.2% | 0.00% | +50.0% |
Q3 2023 | $3,858 | -38.1% | 26,410 | -2.2% | 0.00% | -50.0% |
Q2 2023 | $6,235 | -64.7% | 26,991 | -63.0% | 0.00% | -50.0% |
Q1 2023 | $17,669 | -30.7% | 72,935 | -17.0% | 0.01% | -27.3% |
Q4 2022 | $25,503 | -99.1% | 87,868 | +102.4% | 0.01% | +266.7% |
Q3 2022 | $2,821,000 | +415.7% | 43,415 | +468.3% | 0.00% | – |
Q2 2022 | $547,000 | -40.2% | 7,639 | -18.0% | 0.00% | -100.0% |
Q1 2022 | $914,000 | -63.2% | 9,315 | -68.2% | 0.00% | – |
Q4 2021 | $2,482,000 | +68.2% | 29,292 | +58.2% | 0.00% | -100.0% |
Q3 2021 | $1,476,000 | -8.5% | 18,513 | +11.8% | 0.00% | 0.0% |
Q2 2021 | $1,613,000 | -28.1% | 16,561 | -13.6% | 0.00% | 0.0% |
Q1 2021 | $2,242,000 | +25.8% | 19,168 | +19.6% | 0.00% | 0.0% |
Q4 2020 | $1,782,000 | -13.0% | 16,029 | -7.1% | 0.00% | 0.0% |
Q3 2020 | $2,049,000 | -8.9% | 17,262 | -13.0% | 0.00% | -50.0% |
Q2 2020 | $2,248,000 | +82.9% | 19,837 | +7.8% | 0.00% | +100.0% |
Q1 2020 | $1,229,000 | +1.7% | 18,398 | +38.9% | 0.00% | 0.0% |
Q4 2019 | $1,208,000 | +215.4% | 13,244 | +197.8% | 0.00% | – |
Q3 2019 | $383,000 | -27.5% | 4,448 | -11.8% | 0.00% | – |
Q2 2019 | $528,000 | -75.0% | 5,041 | -70.1% | 0.00% | -100.0% |
Q1 2019 | $2,110,000 | -54.9% | 16,848 | -59.4% | 0.00% | -75.0% |
Q4 2018 | $4,678,000 | -28.2% | 41,502 | +36.4% | 0.00% | 0.0% |
Q3 2018 | $6,516,000 | -3.1% | 30,430 | +26.5% | 0.00% | -33.3% |
Q2 2018 | $6,726,000 | +76.3% | 24,046 | -26.4% | 0.01% | +100.0% |
Q1 2018 | $3,815,000 | +2952.0% | 32,670 | +2293.4% | 0.00% | – |
Q4 2017 | $125,000 | +3025.0% | 1,365 | +1307.2% | 0.00% | – |
Q3 2017 | $4,000 | -50.0% | 97 | -80.0% | 0.00% | – |
Q2 2017 | $8,000 | – | 485 | +12025.0% | 0.00% | – |
Q1 2017 | $0 | – | 4 | 0.0% | 0.00% | – |
Q4 2016 | $0 | – | 4 | 0.0% | 0.00% | – |
Q3 2016 | $0 | – | 4 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Paulson & Co. | 1,850,000 | $518,296,000 | 38.31% |
Tao Capital Management LP | 130,529 | $36,569,005 | 29.98% |
University of Wisconsin Foundation | 45,730 | $12,811,717 | 14.42% |
AlpInvest Partners B.V. | 84,595 | $23,700,135 | 8.50% |
RTW INVESTMENTS, LP | 1,915,862 | $536,747,898 | 8.31% |
Propel Bio Management, LLC | 43,032 | $12,055,845 | 7.82% |
Avoro Capital Advisors LLC | 2,055,555 | $575,884,289 | 7.67% |
Baker Brothers Advisors | 1,974,590 | $553,201,134 | 7.07% |
Tri Locum Partners LP | 65,352 | $18,309,016 | 4.63% |
TCG Crossover Management, LLC | 149,283 | $41,823,125 | 4.36% |